Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an update.
CanSino Biologics Inc. announced that the National Medical Products Administration of China has accepted its new drug application for a tetanus vaccine. This vaccine, which uses an animal-free culture medium for increased safety, primarily targets non-neonatal tetanus prevention. This development is expected to expand CanSino’s product offerings and strengthen its market position.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. operates in the biotechnology industry, focusing on the development and manufacturing of vaccines. The company is known for its work on vaccines for various infectious diseases, aiming to enhance its product pipeline and competitiveness in the market.
YTD Price Performance: -7.30%
Average Trading Volume: 1,261,169
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$9.56B
See more data about 6185 stock on TipRanks’ Stock Analysis page.
